InvestorsHub Logo
Followers 4
Posts 274
Boards Moderated 0
Alias Born 08/12/2019

Re: None

Wednesday, 04/17/2024 1:09:09 PM

Wednesday, April 17, 2024 1:09:09 PM

Post# of 328
"In addition, the company has entered into negotiations with key stakeholders, including warrant holders, to adjust the terms and conditions to make future capital raising more amenable, as well as negotiations to reduce other major liabilities. Finally, the Company has already started raising new equity by utilizing its existing ATM and expects to take further action so Allarity can meet the $2,500,000 equity requirement on the May 14, 2024 target date."

They plan on CONTINUING TO DUMP SHARES on the open market and DILUTING their shareholders with no end in sight.

"Our goal is to ensure that we can continue our development of stenoparib, strongly encouraged by the significant early data we have received so far from our ongoing monotherapy trial in advanced ovarian cancer."


In other words stenoparib is still not ready for phase 3. They are going to have to chemically modify it to try to improve it which means repeating phase 1 and phase 2 trials. They are going to need a A LOT more time and money and there is no guarantee at all that they can get it modified to the point it needs to be at.

This is a TOXIC investment. If there happens to be a pump, sell for what you can and get out. They are just going to continue with the reverse splits followed by dilution for the foreseeable future as they have no revenue, no product, and thomas jackass jensen needs to collect his handsome salary.
Bearish
Bearish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALLR News